US SB3180 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Independent 1-0)
Status: Introduced on January 9 2020 - 25% progression, died in committee
Action: 2020-01-09 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 9 2020 - 25% progression, died in committee
Action: 2020-01-09 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.
Title
Responsibility in Drug Advertising Act of 2020
Sponsors
| Sen. Angus King [I-ME] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-01-09 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB2452 (Related) 2019-05-31 - Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
HB4106 (Same As) 2019-07-31 - Referred to the Subcommittee on Health.
HB4106 (Same As) 2019-07-31 - Referred to the Subcommittee on Health.
Subjects
Drug safety, medical device, and laboratory regulation
Health
Marketing and advertising
Prescription drugs
Health
Marketing and advertising
Prescription drugs
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/senate-bill/3180/all-info |
| Text | https://www.congress.gov/116/bills/s3180/BILLS-116s3180is.pdf |
